Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennøe ØK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lee CH, et al. Among authors: rao a. Lancet Oncol. 2021 Jul;22(7):946-958. doi: 10.1016/S1470-2045(21)00241-2. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143969 Free PMC article. Clinical Trial.
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
de Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, Small EJ, Friedlander T, Fong L, Paris PL, Ryan CJ, Szmulewitz RZ, Aggarwal R. de Kouchkovsky I, et al. Among authors: rao a. Clin Cancer Res. 2022 Apr 14;28(8):1531-1539. doi: 10.1158/1078-0432.CCR-21-4302. Clin Cancer Res. 2022. PMID: 35176163 Clinical Trial.
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.
Lee CH, Yogesh Shah A, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Gironés Sarrió R, Lee Cohn A, Asim Bilen M, Gunnestad Ribe S, Krohn Tennøe Ø, Richards D, Sweis RF, Courtright J, Heinrich D, Perini R, Kubiak P, Bock D, Okpara CE, Motzer RJ. Lee CH, et al. Among authors: rao a. Eur Urol. 2024 Nov;86(5):470-473. doi: 10.1016/j.eururo.2024.05.003. Epub 2024 May 21. Eur Urol. 2024. PMID: 38777648 No abstract available.
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma.
Gulati S, Barata PC, Elliott A, Bilen MA, Burgess EF, Choueiri TK, Darabi S, Dawson NA, Gartrell BA, Hammers HJ, Heath EI, Magee D, Rao A, Ryan CJ, Twardowski P, Wei S, Brugarolas J, Zhang T, Zibelman MR, Nabhan C, McKay RR. Gulati S, et al. Among authors: rao a. J Clin Invest. 2024 May 30;134(14):e176230. doi: 10.1172/JCI176230. J Clin Invest. 2024. PMID: 39007269 Free PMC article.
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ; EORTC-55994 Study Group. Aggarwal R, et al. Among authors: rao a. J Clin Oncol. 2024 Apr 1;42(10):1114-1123. doi: 10.1200/JCO.23.01157. Epub 2024 Jan 23. J Clin Oncol. 2024. PMID: 38261983 Clinical Trial.
6,173 results